KR102606678B1 - 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획 - Google Patents

장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획 Download PDF

Info

Publication number
KR102606678B1
KR102606678B1 KR1020177031672A KR20177031672A KR102606678B1 KR 102606678 B1 KR102606678 B1 KR 102606678B1 KR 1020177031672 A KR1020177031672 A KR 1020177031672A KR 20177031672 A KR20177031672 A KR 20177031672A KR 102606678 B1 KR102606678 B1 KR 102606678B1
Authority
KR
South Korea
Prior art keywords
paliperidone palmitate
patient
depot
dose
month
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177031672A
Other languages
English (en)
Korean (ko)
Other versions
KR20170134583A (ko
Inventor
스리하리 고팔
파울린 게라르다 마리아 라벤스티즌
알베르토 루스수
마헤시 나레인 삼타니
Original Assignee
잔센파마슈티카엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57072843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102606678(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 잔센파마슈티카엔.브이. filed Critical 잔센파마슈티카엔.브이.
Priority to KR1020237040260A priority Critical patent/KR102755145B1/ko
Publication of KR20170134583A publication Critical patent/KR20170134583A/ko
Application granted granted Critical
Publication of KR102606678B1 publication Critical patent/KR102606678B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020177031672A 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획 Active KR102606678B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237040260A KR102755145B1 (ko) 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562144054P 2015-04-07 2015-04-07
US62/144,054 2015-04-07
US201562162596P 2015-05-15 2015-05-15
US62/162,596 2015-05-15
PCT/US2016/024841 WO2016164218A1 (en) 2015-04-07 2016-03-30 Dosing regimen for missed doses for long-acting injectable paliperidone esters

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237040260A Division KR102755145B1 (ko) 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획

Publications (2)

Publication Number Publication Date
KR20170134583A KR20170134583A (ko) 2017-12-06
KR102606678B1 true KR102606678B1 (ko) 2023-11-24

Family

ID=57072843

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020177031672A Active KR102606678B1 (ko) 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획
KR1020257000920A Pending KR20250013293A (ko) 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획
KR1020237040260A Active KR102755145B1 (ko) 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257000920A Pending KR20250013293A (ko) 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획
KR1020237040260A Active KR102755145B1 (ko) 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획

Country Status (27)

Country Link
US (1) US10143693B2 (https=)
EP (3) EP3744326B1 (https=)
JP (3) JP6728221B2 (https=)
KR (3) KR102606678B1 (https=)
AU (4) AU2016244801B2 (https=)
BR (1) BR112017021383A2 (https=)
CA (2) CA2925908C (https=)
CY (1) CY1123203T1 (https=)
DK (2) DK3744326T3 (https=)
EA (1) EA037185B1 (https=)
ES (2) ES2802299T3 (https=)
FI (1) FI3744326T3 (https=)
HR (2) HRP20201027T1 (https=)
HU (2) HUE065435T2 (https=)
IL (3) IL309340B1 (https=)
LT (2) LT3744326T (https=)
MA (1) MA41917B1 (https=)
MD (2) MD3744326T2 (https=)
NZ (1) NZ735952A (https=)
PL (2) PL3744326T3 (https=)
PT (2) PT3280416T (https=)
RS (2) RS65024B1 (https=)
SI (2) SI3280416T1 (https=)
SM (2) SMT202300478T1 (https=)
TW (1) TWI694825B (https=)
UA (1) UA118732C2 (https=)
WO (1) WO2016164218A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016244801B2 (en) 2015-04-07 2020-06-25 Janssen Pharmaceutica Nv Dosing regimen for missed doses for long-acting injectable paliperidone esters
ES3036965T3 (en) * 2017-10-27 2025-09-25 Geneora Pharma Shijiazhuang Co Ltd Dosage regimen of paliperidone palmitate extended-release injectable suspension
IL303254A (en) 2020-11-30 2023-07-01 Janssen Pharmaceutica Nv Methods for ensuring resuspension of paliperidone palmitate formulations
MX2023006368A (es) 2020-11-30 2023-08-07 Janssen Pharmaceutica Nv Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
IL303253A (en) * 2020-11-30 2023-07-01 Janssen Pharmaceutica Nv Dosing regimens associated with delayed-release injectable formulations of paliperidone
PL4025187T3 (pl) 2020-11-30 2024-04-29 Janssen Pharmaceutica Nv Schematy dawkowania związane z formulacjami paliperydonu do wstrzykiwania o przedłużonym uwalnianiu
WO2023021008A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
IL311134A (en) * 2021-08-30 2024-04-01 Janssen Pharmaceutica Nv Dosing regimens associated with delayed-release paliperidone injection formulations
KR102869809B1 (ko) 2023-11-21 2025-10-13 주식회사 엘지에너지솔루션 양극 및 이를 포함하는 전고체 전지

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
EP1879890A1 (en) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
BRPI0821408A2 (pt) * 2007-12-19 2015-06-16 Janssen Pharmaceutica Nv Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação
EP2485712A1 (en) * 2009-10-06 2012-08-15 Ascendis Pharma A/S Subcutaneous paliperidone composition
MX2012005083A (es) * 2009-10-30 2012-09-28 Janssen Pharmaceutica Nv Regimen de dosificacion asociado con esteres de paliperidona inyetables de accion prolongada.
EP2529757B1 (en) * 2011-05-31 2014-01-08 Laboratorios Farmaceuticos Rovi, S.A. Paliperidone implant formulation
AU2016244801B2 (en) 2015-04-07 2020-06-25 Janssen Pharmaceutica Nv Dosing regimen for missed doses for long-acting injectable paliperidone esters

Also Published As

Publication number Publication date
US20170281629A1 (en) 2017-10-05
LT3744326T (lt) 2023-12-27
ES2967585T3 (es) 2024-05-03
EA201792209A1 (ru) 2018-02-28
SMT202300478T1 (it) 2024-01-10
AU2024227790A1 (en) 2024-11-21
HUE065435T2 (hu) 2024-05-28
SMT202000351T1 (it) 2020-09-10
EP4349323A3 (en) 2024-06-12
CY1123203T1 (el) 2021-10-29
KR20250013293A (ko) 2025-01-31
EP3280416A1 (en) 2018-02-14
JP2021130680A (ja) 2021-09-09
JP7228503B2 (ja) 2023-02-24
KR20230162162A (ko) 2023-11-28
TWI694825B (zh) 2020-06-01
IL254669A0 (en) 2017-11-30
EA037185B1 (ru) 2021-02-17
HRP20240022T1 (hr) 2024-03-29
MD3744326T2 (ro) 2024-05-31
FI3744326T3 (fi) 2024-02-02
JP7422277B2 (ja) 2024-01-26
HK1249047A1 (en) 2018-10-26
TW201642863A (zh) 2016-12-16
JP2020090498A (ja) 2020-06-11
JP2018510894A (ja) 2018-04-19
AU2022221405B2 (en) 2024-08-01
PL3744326T3 (pl) 2024-03-25
JP6728221B2 (ja) 2020-07-22
EP4349323A2 (en) 2024-04-10
IL324059A (en) 2025-12-01
SI3744326T1 (sl) 2024-02-29
AU2016244801B2 (en) 2020-06-25
DK3280416T3 (da) 2020-05-11
MA41917B1 (fr) 2020-07-29
KR102755145B1 (ko) 2025-01-14
IL309340B1 (en) 2026-01-01
RS65024B1 (sr) 2024-01-31
DK3744326T3 (da) 2024-02-05
EP3744326B1 (en) 2023-12-06
WO2016164218A1 (en) 2016-10-13
EP3280416A4 (en) 2019-01-23
AU2020239611A1 (en) 2020-10-15
IL309340A (en) 2024-02-01
AU2022221405A1 (en) 2022-09-15
PL3280416T3 (pl) 2020-12-14
CA2925908C (en) 2020-09-01
MD3280416T2 (ro) 2020-10-31
AU2020239611B2 (en) 2022-07-21
HUE049485T2 (hu) 2020-09-28
PT3744326T (pt) 2024-01-15
PT3280416T (pt) 2020-06-30
US10143693B2 (en) 2018-12-04
IL254669B2 (en) 2024-05-01
NZ758246A (en) 2024-05-31
NZ735952A (en) 2022-02-25
RS60510B1 (sr) 2020-08-31
BR112017021383A2 (pt) 2018-07-03
IL254669B1 (en) 2024-01-01
LT3280416T (lt) 2020-06-25
UA118732C2 (uk) 2019-02-25
KR20170134583A (ko) 2017-12-06
SI3280416T1 (sl) 2020-07-31
ES2802299T3 (es) 2021-01-18
AU2016244801A1 (en) 2017-10-05
CA2925908A1 (en) 2016-10-07
EP3280416B1 (en) 2020-04-22
HRP20201027T1 (hr) 2020-12-11
EP3744326A1 (en) 2020-12-02
CA3088401A1 (en) 2016-10-07

Similar Documents

Publication Publication Date Title
AU2022221405B2 (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
JP7792959B2 (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
KR20230116837A (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
KR20230116836A (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
KR20240049580A (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
HK40110149A (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK40044495A (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK40044495B (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK1249047B (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171031

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210224

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20211207

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230216

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230822

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231122

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231122

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231122

End annual number: 3

Start annual number: 1

PG1601 Publication of registration